Form 4: Century Therapeutics' Officer Hyam Levitsky Reports Stock and Option Grants

Hyam Levitsky, President of R&D at Century Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Hyam Levitsky, President of R&D at Century Therapeutics, filed a Form 4 on March 11, 2024, reporting transactions related to Century Therapeutics, Inc. [IPSC].
• On March 7, 2024, Levitsky acquired 24,000 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 146,000 shares of common stock.
• The RSUs vest 25% on March 7, 2025, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• The stock options vest 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
• Levitsky also indirectly owns 536,544 shares of common stock through an irrevocable spousal trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants, which are generally viewed as a positive incentive for management but don't necessarily indicate a strong bullish or bearish outlook.

Positives

• The grant of RSUs and stock options to a key officer like the President of R&D suggests an incentive alignment with the company's long-term performance.
• The vesting schedules for both RSUs and stock options encourage continued service and commitment from the reporting person.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• Vesting schedules are typically structured to align executive incentives with long-term shareholder value creation, often over a 3-4 year period, which is consistent with the vesting terms described in this filing.
• Comparable companies such as CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the grants as an incentive for management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates